Our results collectively demonstrate that tGLI1 and GP130 co-overexpression promote breast CSC phenotypes in HER2-enriched and TNBCs, thereby underscoring their clinical utility to be dual-targeted as a novel combinatorial therapy for breast cancer. The gene discussed is ERBB2; the disease is breast cancer.